DW2008S and its major constituents from Justicia procumbens exert anti‐asthmatic effect via multitargeting activity. Issue 5 (7th March 2018)

• Record Type: Journal Article
• Authors: Youm, Jihyun; Lee, Hyunyong; Choi, Youngwoo; Yoon, Joobyoung
• Is Part Of: Journal of cellular and molecular medicine. Volume 22:Issue 5(2018)
• Page Start: 2680
• Page End: 2691
• Publication Date: 2018-03-07
• Subjects: adenosine receptor A3 -- DW2008S -- Justicia procumbens -- justicidin -- phosphodiesterase 4 -- tyrosine‐based inhibition motif domains; Cytology; Medicine; Molecular Biology; Cytologie -- Périodiques; Médecine -- Périodiques; Biologie moléculaire -- Périodiques; Cytology -- Periodicals; Medicine -- Periodicals; Molecular biology -- Periodicals; 611.01805
• DOI: 10.1111/jcmm.13550
• Languages: English
• ISSNs: 1582-1838

Abstract

Abstract: Our previous study revealed that the ethanolic extract of Justicia procumbens ameliorates ovalbumin‐induced airway inflammation and airway hyper‐responsiveness in a mouse model of asthma. However, the mechanism of action of the extract remains unknown. In this study, we prepared DW2008S, an optimized and standardized powder extracted from J. procumbens using anhydrous ethanol, and investigated its anti‐asthmatic effect and mechanism of action. Our results showed that DW2008S contains two major ingredients, justicidin A (JA) and justicidin B (JB), which selectively inhibit T helper 2 (Th2) cell responses in concanavalin A‐activated spleen cells and polarized Th2 cells. Blockade of T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine‐based inhibition motif domains (TIGIT) using a neutralizing antibody also selectively inhibited Th2 cell responses. Furthermore, DW2008S regulated TIGIT expression in the mice and cultured cells. Additionally, DW2008S and JA antagonized human adenosine receptor A3 (A3 AR), which mediates mast cell‐dependent inflammation and bronchoconstriction. DW2008S and JB inhibited human phosphodiesterase 4 (PDE4), which is known to cause bronchoconstriction; however, the required concentrations were higher than those needed to affect TIGIT . These findings suggest that DW2008S can potentially ameliorate Th2‐driven airway inflammation and bronchoconstriction through negative regulation of TIGIT and blockade of A3 AR and PDE4 activities.